DCGI and institutional ethics committee investigating claim of adverse event in COVID vaccine trial: Officials


PTI, Nov 29, 2020, 4:04 PM IST

New Delhi: The Drugs Controller General of India and the institutional ethics committee at the implementation site are investigating if the adverse event as claimed to have been suffered by a COVID-19 vaccine trial participant in Chennai are related to the shot administered to him.

A 40-year-old Chennai-based business consultant, who was a volunteer for the third phase of the vaccine trial conducted by Pune-based Serum Institute of India (SII), has sought Rs 5 crore compensation for allegedly suffering serious neurological and psychological symptoms after taking the dose.

He was administered the shot at Chennai”s Sri Ramachandra Institute of Higher Education and Research (SRIHER), one of the trial sites on October 1.

A law firm on his behalf has now sent a legal notice to Director General, ICMR, Drugs Controller General of India, Central Drugs Standard Control Organisation, CEO, Astra Zeneca UK, Professor Andrew Pollard, Chief Investigator, Oxford Vaccine Trial and Vice Chancellor of Sri Ramachandra Higher Education and Research.

The man has sought a compensation of Rs 5 crore and that the testing, manufacturing and distribution of the vaccine be stopped immediately.

Dr Samiran Panda, who heads the Epidemiology and Communicable Diseases (ECD) division of the ICMR, said the causal link, if any, of the serious adverse events with the investigational product is objectively assessed in any clinical trial following a pre-defined scientific pathway and within a stipulated period.

“Any hurried inquiry or inference is prone to be wrong. Both the institutional ethics committee and the DCGI are investigating the causal links, if any, between the adverse events and investigational product, which is an anti-coronavirus vaccine,” Dr Panda said.

The SII has partnered with British-Swedish biopharmaceutical giant AstraZeneca AstraZeneca for manufacturing the Oxford vaccine candidate for COVID-19.

The DCGI had on September 11 directed Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of ””an unexplained illness”” in a participant in the study.

However, on September 15 it permitted the Serum Institute of India to recommence the trial.

The notice given on November 21 by the law firm said, “Our client states that he must be compensated, in the least, for all the sufferings that he and his family have undergone and are likely to undergo in future.”

“He further states that he is still far from being all right and has to be under medical care for a long time to come. Therefore, for all the trauma he is undergoing and with an uncertain future in his health, he should be given a financial compensation of Rs. 5 crores within two weeks from the receipt of this notice,” it said.

The notice also said that testing, manufacturing and the distribution of the vaccine should also be stopped immediately, “failing which he has no other option except to take appropriate legal action against all the concerned parties, who would be made responsible for all the costs and consequences”.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Maha: One dead in road accident in Chandrapur district

China says latest round of talks with India on border issue ‘positive and constructive’; slams White House official’s remarks

Karnataka legislature joint session from Feb 14, budget in March first week

He didn’t want the money, he just wanted to play: Looking back at Deepak Hooda’s rollercaster ride

‘Badhaai Do’ humour not at the expense of LGBTQI community, it’s a sensitive film: Bhumi Pednekar

‘Goonda raj’ to return if Akhilesh forms govt in UP: Shah

Hockey legend Charanjit Singh dies


Related Articles More

Kerala witnessing Omicron wave, says Minister

48,905 new COVID-19 cases in Karnataka, 39 deaths

Should handle COVID-19 third wave with ‘total seriousness’: Thaawar Chand Gehlot

WHO: Record weekly COVID cases last week but deaths stable

Each dose of Covishield, Covaxin likely to be capped at Rs 275 after getting regular market approval

MUST WATCH

History and Significance of Barkur

Udayavani News Bulletin 27-1-2022

A Crow In Obalapura Village In Chitradurga Is Attacking 7 People

DK Shivakumar Press meet

Hindu Vahini members manhandled, detained by Guntur Police


Latest Additions

Maha: One dead in road accident in Chandrapur district

Kerala witnessing Omicron wave, says Minister

Man gunned down in high-security area of Ranchi

China says latest round of talks with India on border issue ‘positive and constructive’; slams White House official’s remarks

Nadda forms 4-member panel to probe TN girl’s death by suicide

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.